AstraZeneca Released Satisfactory Results of 24 Weeks CALYPSO Phase III Trial for Eneboparatide
Trial continues as planned to 52 weeks to further characterize the risk-benefit profile.
Editor's Desk
Amgen Released Phase 3 MINT Trial Data Evaluating the Efficacy and Safety of UPLIZNA® (inebilizumab-cdon)
The trial achieved its primary endpoint, as previously revealed at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting.
Merck Announces Positive Results of Phase 3 Trials for Their HIV-1 Investigational Two-Drug Regimen Doravirine/Islatravir
Islatravir, Merck’s investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI), inhibits HIV-1 replication through a variety of mechanisms
Researchers Developed a More Affordable, Lower-risk Polio Vaccine
The current inactivated polio vaccine (IPV), which uses a destroyed form of the poliovirus to trigger an immune system response
Pfizer With Arvinas Announced Positive Results of Phase 3 VERITAC-2 Clinical Trial for Advanced or Metastatic Breast Cancer
At the time of the analysis, less than 25% of the necessary number of events had taken place, indicating that overall survival was not mature.
Novo Nordisk’s CagriSema for Obesity and Type 2 Diabetes Shows Superior Results in REDEFINE 2 Trial
CagriSema showed a statistically significant and superior weight loss at week 68 compared to placebo, meeting the trial’s primary aim.
Johnson & Johnson Discontinued VENTURA Drug Development Program
The Phase 3 VENTURA research study, which was assessing aticaprant as an adjunctive treatment for major depressive disorder (aMDD), has been discontinued by Johnson & [Read More…]
Over-the-counter Painkillers Were Associated With Better Concussion Recovery
The study merely demonstrates a connection rather than proving that painkillers enhance concussion recovery.
Roche’s Supplemental Biologics License Application of Gazyva/Gazyvaro (Obinutuzumab) for The Treatment of Lupus Nephritis Accepted by U.S. FDA
In a randomized phase III study, Gazyva®/Gazyvaro® is the only anti-CD20 monoclonal antibody that shows a full renal response benefit.
AbbVie Enters Into the Obesity Drug Market With a License Agreement
GUB014295 is a calcitonin and amylin receptor-specific agonist that may be a long-acting amylin analog.
